Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Can Cannabis Cannabinoids Reduce Brain Inflammation in Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Brain inflammation, or neuroinflammation, is believed to play a major role in the progression of dementia. This process involves overactive immune cells in the brain that release inflammatory molecules, potentially damaging neurons, and accelerating cognitive decline. Because cannabinoids can influence inflammation in laboratory studies, researchers have questioned whether cannabis might help protect the brain in dementia. 

However, according to NHS and NICE guidance, there is no clinical evidence showing that cannabis-based medicines reduce brain inflammation or slow dementia progression in humans (NHS Guidance; NICE NG144). 

Can medical cannabis be accessed legally for women’s health?

What The Research Shows 

Laboratory And Animal Studies 

Preclinical studies have found that cannabinoids such as THC and CBD interact with the brain’s endocannabinoid system (ECS), influencing receptors (CB1 and CB2) involved in inflammation and immune activity. In animal models of Alzheimer’s disease, cannabinoids reduced inflammatory markers and prevented some nerve cell damage. 

A 2024 review published in Frontiers in Aging Neuroscience by researchers from the Johns Hopkins Center for Psychedelic and Consciousness Research concluded that cannabinoids show anti-inflammatory potential in theory but that this has not translated into proven clinical benefit in dementia patients (Frontiers in Aging Neuroscience, 2024). 

Human Clinical Evidence 

To date, no clinical trials have shown that cannabinoids reduce brain inflammation in people with dementia. Studies such as the 2023 randomised trial of THC/CBD formulations found no significant improvements in cognition or biomarkers of inflammation (PubMed Study). 

A 2024 systematic review in Nature Reviews Neurology examined cannabinoid pathways and Alzheimer’s disease neurobiology. It concluded that cannabinoids show anti-inflammatory potential at the cellular level, particularly in reducing amyloid-related immune activation, but that human data are inconclusive and clinical translation remains uncertain (Nature Reviews Neurology, 2024). 

Additionally, a 2024 Swiss feasibility study found oral THC/CBD oil was safe and tolerated in people with severe dementia, but no measurable reduction in inflammatory or behavioural symptoms was seen (Swiss Study, 2024). 

The Clinical Bottom Line 

  • Cannabinoids show anti-inflammatory effects in laboratory and animal models. 
  • No human studies confirm reduced brain inflammation or slower dementia progression. 
  • NICE, NHS, and WHO do not recommend cannabis for neuroinflammatory or cognitive treatment. 
  • Research remains ongoing but limited to early experimental stages. 

Educational Context: AlleviMed 

Educational organisations such as AlleviMed provide information on how cannabis eligibility is assessed in the UK. They clarify that cannabis-based medicines are licensed only for specific conditions, not for reducing brain inflammation or treating dementia. 

Takeaway 

Although cannabinoids can reduce inflammation in laboratory settings, no human studies show that cannabis reduces brain inflammation or slows dementia. According to NHS, NICE, and Johns Hopkins experts, these findings remain theoretical and unproven in clinical practice. Any use should be limited to formal research trials. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories